Na Xu

739 total citations
44 papers, 452 citations indexed

About

Na Xu is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Na Xu has authored 44 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Na Xu's work include Acute Myocardial Infarction Research (6 papers), Gout, Hyperuricemia, Uric Acid (5 papers) and Coronary Interventions and Diagnostics (3 papers). Na Xu is often cited by papers focused on Acute Myocardial Infarction Research (6 papers), Gout, Hyperuricemia, Uric Acid (5 papers) and Coronary Interventions and Diagnostics (3 papers). Na Xu collaborates with scholars based in China, United States and Australia. Na Xu's co-authors include Tomáš Roubíček, Garvan C. Kane, Vesna D. Garovic, Anthony W. Stanson, Bo Xu, Yi Yao, Xiaofang Tang, Baisong Zheng, Yiming Cao and Zhan Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Na Xu

40 papers receiving 441 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Na Xu China 11 116 110 106 104 62 44 452
Ciprian Jurcuț Romania 14 65 0.6× 58 0.5× 130 1.2× 124 1.2× 146 2.4× 67 649
Vasiliki-Kalliopi Bournia Greece 15 48 0.4× 97 0.9× 74 0.7× 73 0.7× 114 1.8× 35 589
Nahum Calvo Spain 11 69 0.6× 85 0.8× 65 0.6× 80 0.8× 25 0.4× 23 533
Bryce D. Beutler United States 12 66 0.6× 105 1.0× 103 1.0× 78 0.8× 24 0.4× 86 586
Daisuke Hoshi Japan 15 28 0.2× 142 1.3× 55 0.5× 90 0.9× 112 1.8× 53 792
Wanhai Wang China 9 54 0.5× 84 0.8× 82 0.8× 140 1.3× 62 1.0× 12 600
Jan Van Keer Belgium 11 83 0.7× 58 0.5× 129 1.2× 55 0.5× 74 1.2× 30 387
Maribel Quezada-Feijoó Spain 15 207 1.8× 63 0.6× 69 0.7× 91 0.9× 112 1.8× 37 542
J.W. van der Pijl Netherlands 14 76 0.7× 40 0.4× 322 3.0× 61 0.6× 60 1.0× 25 701
Josiane Bourré‐Tessier Canada 13 55 0.5× 46 0.4× 56 0.5× 191 1.8× 121 2.0× 28 518

Countries citing papers authored by Na Xu

Since Specialization
Citations

This map shows the geographic impact of Na Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Na Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Na Xu more than expected).

Fields of papers citing papers by Na Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Na Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Na Xu. The network helps show where Na Xu may publish in the future.

Co-authorship network of co-authors of Na Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Na Xu. A scholar is included among the top collaborators of Na Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Na Xu. Na Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Lianbo, Lijuan Kang, Songtao Xue, et al.. (2024). 807MO High efficacy and safety of interleukin-6-knockdown CD19-targeted CAR-T cells in relapsed/refractory B-ALL patients. Annals of Oncology. 35. S599–S599. 1 indexed citations
2.
Yu, Lu, Weiming Li, Na Xu, et al.. (2024). Patient‐reported outcomes in adults with tyrosine kinase inhibitor‐resistant chronic myeloid leukemia receiving olverembatinib therapy. Cancer. 131(1). e35652–e35652. 1 indexed citations
3.
Zhang, Yanli, Huanling Zhu, Na Xu, et al.. (2024). Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML). Blood. 144(Supplement 1). 480–480. 1 indexed citations
4.
5.
Xu, Na, et al.. (2023). Particle implantation combined with chemotherapy for rhabdomyosarcoma of the head and neck: A 8‐year long‐term follow‐up case report. SHILAP Revista de lepidopterología. 2(3). 233–236. 1 indexed citations
6.
7.
Wang, Xiaozeng, Zhenyu Liu, Zheng Zhang, et al.. (2023). Inflammation and Insulin Resistance in Diabetic Chronic Coronary Syndrome Patients. Nutrients. 15(12). 2808–2808. 34 indexed citations
8.
Xu, Na, et al.. (2023). α-Synuclein Aggregates in the Nigro-Striatal Dopaminergic Pathway Impair Fine Movement: Partial Reversal by the Adenosine A2A Receptor Antagonist. International Journal of Molecular Sciences. 24(2). 1365–1365. 3 indexed citations
9.
Xu, Na, Pei Zhu, Lin Jiang, et al.. (2022). Big Endothelin-1 and long-term all-cause death in patients with coronary artery disease and prediabetes or diabetes after percutaneous coronary intervention. Nutrition Metabolism and Cardiovascular Diseases. 32(9). 2147–2156. 2 indexed citations
10.
Xu, Na, Hongsheng Zhou, Di Wu, et al.. (2022). Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome. Frontiers in Oncology. 12. 893928–893928. 1 indexed citations
11.
Xu, Na, Yun Zhang, Xiaoming Huang, et al.. (2022). Clinical features of gout in adult patients with type Ia glycogen storage disease: a single-centre retrospective study and a review of literature. Arthritis Research & Therapy. 24(1). 58–58. 4 indexed citations
12.
Zhang, Bingqing, Yang Sun, Na Xu, et al.. (2021). Adult-onset deficiency of adenosine deaminase 2—a case report and literature review. Clinical Rheumatology. 40(10). 4325–4339. 7 indexed citations
13.
Xu, Na, et al.. (2020). Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan, China. European Journal of Hospital Pharmacy. 29(4). 217–221. 8 indexed citations
14.
Gao, Fan, Wentao Zhang, Y. Lin, et al.. (2019). <p>Early Start Of Tenofovir Treatment Achieves Better Viral Suppression In Pregnant Women With A High HBV Viral Load: A Real-World Prospective Study</p>. Infection and Drug Resistance. Volume 12. 3475–3484. 9 indexed citations
15.
Xu, Na, et al.. (2019). The early diagnosis of Parkinson's disease through combined biomarkers. Acta Neurologica Scandinavica. 140(4). 268–273. 10 indexed citations
16.
Liu, Yue, Yi Yao, Xiaofang Tang, et al.. (2019). Evaluation of a novel score for predicting 2-year outcomes in patients with acute coronary syndrome after percutaneous coronary intervention. Journal of the Chinese Medical Association. 82(8). 616–622. 1 indexed citations
17.
Xu, Na, Hongwei Fan, Weiguo Zhu, et al.. (2018). [Clinical features of adult patients with chronic active Epstein-Barr virus infection].. PubMed. 57(11). 811–815. 2 indexed citations
18.
Xue, Dong, et al.. (2013). Correlation Between CD14+CD16++ Monocytes in Peripheral Blood and Hypertriglyceridemia After Allograft Renal Transplantation. Transplantation Proceedings. 45(9). 3279–3283. 2 indexed citations
19.
Wang, Li, et al.. (2013). Electrophysiological Characteristics of the Pediatric Femoral Nerve and Their Use in Clinical Diagnosis. Pediatric Neurology. 50(2). 149–157. 3 indexed citations
20.
Kane, Garvan C., et al.. (2009). Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis. Nephrology Dialysis Transplantation. 25(3). 813–820. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ciprian Jurcuț Breakdown of academic impact, for papers by Vasiliki-Kalliopi Bournia Breakdown of academic impact, for papers by Nahum Calvo Breakdown of academic impact, for papers by Bryce D. Beutler Breakdown of academic impact, for papers by Daisuke Hoshi Breakdown of academic impact, for papers by Wanhai Wang Breakdown of academic impact, for papers by Jan Van Keer Breakdown of academic impact, for papers by Maribel Quezada-Feijoó Breakdown of academic impact, for papers by J.W. van der Pijl Breakdown of academic impact, for papers by Josiane Bourré‐Tessier
Rankless by CCL
2026